1-2 of 2
Eva M. Lepisto, MSc, MA
Close
Sort by
Journal Articles

R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project.

Ann LaCasce, MD, Jonathan L. Vandergrift, MS, Maria A. Rodriguez, MD, Allison L. Crosby, MS, Eva M. Lepisto, MSc, MA, Myron S. Czuczman, MD, Auayporn P. Nademanee, MD, Douglas W. Blayney, MD, Leo I. Gordon, MD, Michael Millenson, MD, Ann Vanderplas, Gregory A. Abel, MD, MPH, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2009) 114 (22): 403.
https://doi.org/10.1182/blood.V114.22.403.403
Published: 2009
Journal Articles

Evolution of Rituximab as “Standard” Therapy in Patients (pts) with Newly Diagnosed Follicular (FL), Mantle Cell (MCL), and Diffuse Large B Cell (DLCL) Non-Hodgkin’s Lymphoma (NHL) in 5 United States Comprehensive Cancer Centers: An Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project.

Jonathan W. Friedberg, MD, MMSc, Michelle E. Kho, PT, MSc, Eva M. Lepisto, MSc, MA, M. Alma Rodriguez, MD, Anna TerVeer, MSc, Ann S. LaCasce, MD, Auyporn P. Nademanee, MD, Michael Millenson, MD, Myron Czuczman, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD, PhD, Jane C. Weeks, MD, MSc
Journal: Blood
Blood (2004) 104 (11): 1391.
https://doi.org/10.1182/blood.V104.11.1391.1391
Published: 2004